Media coverage about Trinity Biotech PLC (NASDAQ:TRIB) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Trinity Biotech PLC earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.1750688594319 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Separately, Zacks Investment Research upgraded shares of Trinity Biotech PLC from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research note on Tuesday, July 25th.

Shares of Trinity Biotech PLC (NASDAQ TRIB) opened at $4.82 on Tuesday. Trinity Biotech PLC has a 52 week low of $4.22 and a 52 week high of $7.40. The company has a quick ratio of 3.77, a current ratio of 5.16 and a debt-to-equity ratio of 0.90. The company has a market cap of $119.72, a price-to-earnings ratio of 83.00 and a beta of 1.42.

Trinity Biotech PLC (NASDAQ:TRIB) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.03. Trinity Biotech PLC had a positive return on equity of 5.87% and a negative net margin of 100.00%. The business had revenue of $25.60 million during the quarter, compared to analysts’ expectations of $25.52 million. sell-side analysts expect that Trinity Biotech PLC will post 0.06 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at

About Trinity Biotech PLC

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

Insider Buying and Selling by Quarter for Trinity Biotech PLC (NASDAQ:TRIB)

Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.